Asset
TECOVIRIMAT
SIGA Technologies Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02474589 | phase3 | completed | 2015-06-19 | 2016-08-24 | SIGA Technologies | A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat |
| NCT04485039 | phase4 | completed | 2022-06-08 | 2022-12-15 | SIGA Technologies | Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders |
| NCT00431951 | phase1 | completed | 2007-02-01 | 2008-02-01 | SIGA Technologies | Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers |
| NCT00907803 | phase2 | completed | 2009-06-01 | 2010-01-01 | SIGA Technologies | Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246 |
| NCT04957485 | phase2 | active_not_recruiting | 2022-04-05 | 2027-01-01 | SIGA Technologies | Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS |
FDA applications (2)
| Application | Type | Applicant |
|---|---|---|
| NDA 208627 | NDA | SIGA TECHNOLOGIES INC |
| NDA 214518 | NDA | SIGA TECHNOLOGIES INC |
Marketed products (2)
- TPOXX
- TPOXX